First-in-Human Phase 1 Safety, Pharmacokinetic, and Food Effect Study of Single Ascending Doses of G1T38 in Healthy Male and Female Subjects

Trial Profile

First-in-Human Phase 1 Safety, Pharmacokinetic, and Food Effect Study of Single Ascending Doses of G1T38 in Healthy Male and Female Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 21 Jun 2017

At a glance

  • Drugs G1T 38 (Primary)
  • Indications Cancer
  • Focus Adverse reactions; First in man
  • Sponsors G1 Therapeutics
  • Most Recent Events

    • 01 May 2017 Status changed from active, no longer recruiting to completed.
    • 06 Jan 2017 Planned End Date changed from 1 Dec 2016 to 1 Mar 2017.
    • 07 Dec 2016 Planned number of patients changed from 69 to 75.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top